Crizotinib has also been shown to have activity against the 1-2% of patients with NSCLC that show rearrangements of another receptor tyrosine kinase gene, ROS1, located at 6q22[5,9]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.